|
|
|
Volumn 4, Issue 9, 2003, Pages 1046-1047
|
|
Is there a 'treatment gap' in acute coronary syndromes?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTILIPEMIC AGENT;
APOLIPOPROTEIN A1;
CHOLESTEROL;
D 4F;
ETC 216;
HIGH DENSITY LIPOPROTEIN;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
MEVINOLIN;
PHOSPHOLIPID;
PRAVASTATIN;
PROBUCOL SUCCINATE;
SIMVASTATIN;
UNCLASSIFIED DRUG;
ATHEROSCLEROTIC PLAQUE;
CHOLESTEROL BLOOD LEVEL;
CLINICAL TRIAL;
CORONARY STENT;
DEATH;
DRUG EFFECT;
DRUG EFFICACY;
DRUG INDICATION;
DRUG MEGADOSE;
DRUG SAFETY;
DRUG USE;
EDITORIAL;
GENE THERAPY;
GENE TRANSFER;
HEART INFARCTION;
HEART MUSCLE ISCHEMIA;
HIGH RISK PATIENT;
HUMAN;
HYPERCHOLESTEROLEMIA;
ISCHEMIC HEART DISEASE;
NONHUMAN;
SECONDARY PREVENTION;
TRANSLUMINAL CORONARY ANGIOPLASTY;
ACUTE DISEASE;
ANGINA, UNSTABLE;
ANIMALS;
ANTICHOLESTEREMIC AGENTS;
APOLIPOPROTEIN A-I;
CHOLESTEROL, LDL;
CORONARY VESSELS;
HUMANS;
HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;
MYOCARDIAL INFARCTION;
SYNDROME;
|
|
EID: 0142152237
PISSN: 14724472
EISSN: None
Source Type: Journal
DOI: None Document Type: Editorial |
|
Times cited : (2)
|
|
References (0)
|
